245 related articles for article (PubMed ID: 35510387)
21. MicroRNA-4735-3p Facilitates Ferroptosis in Clear Cell Renal Cell Carcinoma by Targeting SLC40A1.
Zhu C; Song Z; Chen Z; Lin T; Lin H; Xu Z; Ai F; Zheng S
Anal Cell Pathol (Amst); 2022; 2022():4213401. PubMed ID: 35646516
[TBL] [Abstract][Full Text] [Related]
22. Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma.
Fu Y; Piao C; Zhang Z; Zhu Y; Sun S; Bi J; Kong C; Ju M
Urol Oncol; 2020 Sep; 38(9):740.e1-740.e9. PubMed ID: 32402768
[TBL] [Abstract][Full Text] [Related]
23. HO-1 Contributes to Luteolin-Triggered Ferroptosis in Clear Cell Renal Cell Carcinoma via Increasing the Labile Iron Pool and Promoting Lipid Peroxidation.
Han S; Lin F; Qi Y; Liu C; Zhou L; Xia Y; Chen K; Xing J; Liu Z; Yu W; Zhang Y; Zhou X; Rao T; Cheng F
Oxid Med Cell Longev; 2022; 2022():3846217. PubMed ID: 35656025
[TBL] [Abstract][Full Text] [Related]
24. Exploring a ferroptosis and oxidative stress-based prognostic model for clear cell renal cell carcinoma.
Lin D; Hu B; Zhu S; Wu Y
Front Oncol; 2023; 13():1131473. PubMed ID: 37064095
[TBL] [Abstract][Full Text] [Related]
25. Pyruvate transamination and NAD biosynthesis enable proliferation of succinate dehydrogenase-deficient cells by supporting aerobic glycolysis.
Ricci L; Stanley FU; Eberhart T; Mainini F; Sumpton D; Cardaci S
Cell Death Dis; 2023 Jul; 14(7):403. PubMed ID: 37414778
[TBL] [Abstract][Full Text] [Related]
26. CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances sorafenib sensitivity via the ROS/PPARγ/NF-κB pathway in clear cell renal cell carcinoma.
Zeng K; Li Q; Song G; Chen B; Luo M; Miao J; Liu B
Cell Signal; 2023 Oct; 110():110838. PubMed ID: 37541641
[TBL] [Abstract][Full Text] [Related]
27. MITD1 Deficiency Suppresses Clear Cell Renal Cell Carcinoma Growth and Migration by Inducing Ferroptosis through the TAZ/SLC7A11 Pathway.
Zhang Y; Li Y; Qiu Q; Chen Z; Du Y; Liu X
Oxid Med Cell Longev; 2022; 2022():7560569. PubMed ID: 36046690
[TBL] [Abstract][Full Text] [Related]
28. A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma.
Wu G; Wang Q; Xu Y; Li Q; Cheng L
Aging (Albany NY); 2020 Jul; 12(14):14933-14948. PubMed ID: 32688345
[TBL] [Abstract][Full Text] [Related]
29. [Succinate dehydrogenase (SDH)-deficient renal cell carcinoma].
Agaimy A
Pathologe; 2016 Mar; 37(2):144-52. PubMed ID: 26979428
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
31. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
[TBL] [Abstract][Full Text] [Related]
32. ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma.
Qiu X; Gu Y; Ni Y; Li Q
Biomed Res Int; 2020; 2020():2064582. PubMed ID: 33178820
[TBL] [Abstract][Full Text] [Related]
33. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
34. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis.
Cardaci S; Zheng L; MacKay G; van den Broek NJ; MacKenzie ED; Nixon C; Stevenson D; Tumanov S; Bulusu V; Kamphorst JJ; Vazquez A; Fleming S; Schiavi F; Kalna G; Blyth K; Strathdee D; Gottlieb E
Nat Cell Biol; 2015 Oct; 17(10):1317-26. PubMed ID: 26302408
[TBL] [Abstract][Full Text] [Related]
35. Metabolic signatures of renal cell carcinoma.
Lim HY; Yip YM; Chiong E; Tiong HY; Halliwell B; Esuvaranathan K; Wong KP
Biochem Biophys Res Commun; 2015 May; 460(4):938-43. PubMed ID: 25839656
[TBL] [Abstract][Full Text] [Related]
36. The induction of ferroptosis by KLF11/NCOA4 axis: the inhibitory role in clear cell renal cell carcinoma.
Zhou ZQ; Lv X; Liu SB; Qu HC; Xie QP; Sun LF; Li G
Hum Cell; 2023 Nov; 36(6):2162-2178. PubMed ID: 37642832
[TBL] [Abstract][Full Text] [Related]
37. Assembly of mitochondrial succinate dehydrogenase in human health and disease.
Cao K; Xu J; Cao W; Wang X; Lv W; Zeng M; Zou X; Liu J; Feng Z
Free Radic Biol Med; 2023 Oct; 207():247-259. PubMed ID: 37490987
[TBL] [Abstract][Full Text] [Related]
38. Genetic, epigenetic and biochemical regulation of succinate dehydrogenase function.
Moosavi B; Zhu XL; Yang WC; Yang GF
Biol Chem; 2020 Feb; 401(3):319-330. PubMed ID: 31408429
[TBL] [Abstract][Full Text] [Related]
39. Decreased Expression of ACADSB Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma.
Liu X; Zhang W; Wang H; Zhu L; Xu K
Front Oncol; 2021; 11():762629. PubMed ID: 35096573
[TBL] [Abstract][Full Text] [Related]
40. KLF2 inhibits cancer cell migration and invasion by regulating ferroptosis through GPX4 in clear cell renal cell carcinoma.
Lu Y; Qin H; Jiang B; Lu W; Hao J; Cao W; Du L; Chen W; Zhao X; Guo H
Cancer Lett; 2021 Dec; 522():1-13. PubMed ID: 34520818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
